Roche, Pfizer win FDA nods for targeted cancer drugs

Roche ($RHHBY) and Genentech won a landmark approval for the cancer drug vismodegib today. After gaining significant efficacy data from a Phase II study on basal cell carcinoma, the drug giant not only went straight to the regulators for a decision, but also won the approval well ahead of the agency's deadline. And top regulators signaled that they would look kindly on other developers who take the same approach to targeted therapeutics. The FDA nod comes on top of another targeted-drug approval Friday, for Pfizer's ($PFE) advanced kidney cancer drug axitinib, which will be marketed as Inlyta. Article | Report

Suggested Articles

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.